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ABSTRACT
The Transient Receptor Potential Vanilloid type-1 (TRPV1) channel is a non-
selective cation channel belonging to the Transient Receptor Potential family; variation 
of its expression has been correlated to glioma progression. In human, TRPV1 
transcripts display a remarkable homogeneity differing only for the 5'-untranslated 
region (5’UTR) sequence that generates four variants encoding the same protein. 
Herein, we investigated the role of the 5’UTR sequences in TRPV1 transcripts stability, 
regulation of translation, expression in glioma cells and tissues. In addition, the 
expression of 5’UTR TRPV1 variants as prognostic factor in the survival of glioblastoma 
patients was evaluated. The expression level for each 5’UTR and their stability 
was evaluated by RT-PCR analysis. The effect of rapamycin and interferon-gamma 
in 5’UTR-regulating TRPV1 translation was determined by western blot analysis 
in glioma cell lines. We demonstrated that the 5’UTR influences the stability and 
translation efficacy of TRPV1 transcripts, and that TRPV1 variant three (TRPV1v3) 
was the most stable and the only variant expressed in GBM samples and in glioma 
stem-like cells. Furthermore, we found that TRPV1v3 expression levels correlate with 
patient’s survival, suggesting that it may represent a potential prognostic marker for 
patients with glioma.
INTRODUCTION
The Transient Receptor Potential Vanilloid type-
1 (TRPV1) channel is a non-selective cation channel 
structurally related to members of the Transient Receptor 
Potential (TRP) family. The gene encoding the human 
TRPV1 (ENSG00000196689) is located on Chromosome 
17: 3,565,444-3,609,411 reverse strand and covers a region 
of 44 Kb. The canonical form of TRPV1 comprises 839 aa 
(MW ≈ 96 kDa) and is composed of six trans-membrane 
spanning domains and a pore loop domain between 
trans-membrane domains 5 and 6 [1]. The N-terminal 
and C-terminal tails are on the cytoplasmic side. Three 
N-terminal ankyrin (ANK) repeats spanning amino acids 
101-304 are present in N-terminal tail [2]. In TRP channel 
families, alternative splicing enables the same gene to 
generate multiple mature RNA types for translation, 
resulting in multiple channel proteins [3]. At present three 
different TRPV1 splice variants have been identified: 
the Vanilloid Receptor 5’ splice variant (VR.5’sc), the 
TRPV1beta (TRPV1β) and the TRPV1variant (TRPV1var) 
[4]. The VR.5’sc variant, identified in rat, originates 
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from an alternative initiation of translation resulting in 
a truncated N-terminal intracellular domain and on the 
skipping of an exon, resulting in the loss of 60 aa encoding 
for a N-terminal intra-terminal region including the third 
ankyrin repeat domain; the TRPV1β, described in a human 
clone that lacked exon 7 (30 nucleotide loss) encoding a 
portion of the third ankyrin repeat domain [5]; TRPV1var 
isolated from rat kidney papilla resulting from the failure 
to splice out intron 5 [6]. In addition, although TRPV1 
transcripts display a remarkable homogeneity in the open 
reading frame and in the 3’-untranslated regions (3’UTR), 
different 5'-untranslated region (5’UTR) sequence due to 
alternative 1st exon, generates four variants (TRPV1v1, 
TRPV1v2, TRPV1v3, TRPV1v4) encoding the same protein, 
with TRPV1v2 sharing 100% homology with TRPV1 
wild type (TRPV1v0). In-frame stop codon immediately 
upstream of the translation start site ensures that the 5’ 
variability occurs at the mRNA level, with only the 5’UTR 
affected by the alternative 1st exon [2]. The 5’UTR is a 
major site of regulation of translation, since it contains 
both cis- and trans-acting elements that contribute to 
qualitative and quantitative regulation of this process 
[7]. Elements in 5’UTR, such as upstream open reading 
frames (uORFs), internal ribosome entry sites (IRES) [8, 
9], RNA G-quadruplexes [10], terminal oligopyrimidine 
tract (TOP) [11], gamma interferon activated inhibitor 
of ceruloplasmin mRNA translation (GAIT) [12], have 
been demonstrated to affect translation. In addition, the 
length and the GC content in the 5’UTR can influence 
the translation of the main ORFs [13, 14]. So, 5’UTR 
elements can influence regulation of gene expression and 
are associated with the development of human diseases by 
controlling mRNA stability and translational efficiency, as 
in cancer [15]. In human cancer, TRPV1 has been found to 
activate a cell death program in prostate [16], colon [17], 
pancreas [18], breast [19] and bladder cancer [20, 21]. 
Moreover, TRPV1 is also involved in glioma progression 
and changes of its expression contribute to malignancy. 
We have previously reported that TRPV1 is expressed 
in glioma tissues but not in epileptic brain tissues, with 
an inverse correlation between TRPV1 expression levels 
and pathological glioma grade [22]. Moreover, neural 
precursor cell stimulation of TRPV1 has been found to 
trigger high-grade glioma cell death, activating the ATF3 
transcription factor controlling ER stress pathway [23, 
24]. Finally, it has been recently reported at mRNA level, 
that TRPV1 was over-expressed in glioblastoma (GBM) 
patients with higher overall survival (OS, more than 12 
months) as respect to those showing lower OS (less than 
12 months) [25]. Since 5’UTRs of the human TRPV1 
transcripts could play a role in TRPV1 stability and 
translational efficiency, we investigated the involvement 
of 5’UTR sequences in TRPV1 stability, regulation of 
TRPV1 protein synthesis and expression in GBM cell 
lines. Moreover, the expression of 5’UTR TRPV1 variants 
in GBM, glioma stem-like cells (GSCs) and the 5’UTR 
TRPV1 variants role as prognostic factor in the survival 
of GBM patients have been evaluated.
RESULTS
The 5'UTR regions influence the RNA secondary 
structure of TRPV1 transcripts
The 5’UTR of TRPV1 mRNA transcripts were 
selected from the mRNA sequences available in 
UNIGENE database. Five 5’UTR variants, named 
TRPV1v0-4, were present and they differed for the length 
of 5’UTR (Table 1), except for TRPV1vo and TRPV1v2 
that showed 100% nucleotide sequence homology. ORF 
and 3’UTR regions, showed 100% nucleotide sequence 
homology in all the TRPV1 5’UTR variants. Therefore, 
for the structure analysis of TRPV1 5’UTR we selected 
TRPV1v0, v1, v3, v4 variants. First, the evaluation of 
the 5’UTR length and GC content evidenced that the 
TRPV1v3 is the longest (527 nt), followed by TRPV1v1 
(275 nt), TRPV1v4 (201 nt) and TRPV1v0 (158 nt), while 
GC content was higher in TRPV1v0 (65.8%), followed 
by TRPVv3 (62.2%), TRPV1v1 (58.2%) and TRPV1v4 
(54.7%) (Supplementary Table 1). Since the 5’UTR 
sequence appeared to influence the overall topology of 
the complete mRNA and the GC content was correlated 
with the thermodynamic stability of RNA secondary 
structure, we predicted the free energy of the secondary 
structure both of 5’UTRs and of the full length TRPV1 
5’UTR variant sequences, using the mFold software. As 
shown (Figure 1) the TRPV1v3 transcript has the lower 
free energy, followed by TRPVv4, TRPV1v1 and TRPVv0, 
while considering the 5’UTR, TRPV1v3 lower free energy 
was followed by that of TRPV1v1, TRPV1v4 and TRPV1v0. 
Overall, for any TRPV1 variant, we evaluated the RNA 
sequence length, the GC content and the estimated free 
energy. Since the mRNA with the most negative value of 
free energy is considered the most structured and the most 
stable, these results suggest that TRPV1v3 should be the 
most stable TRPV1 variant transcript.
The 5’UTR modulates the half-life of TRPV1 
variant transcripts
In order to investigate the role of the 5’UTR in 
regulating mRNA stability, we measured the half-life of 
the TRPV1 5’UTR variant mRNAs, in U87 and U251 
glioma cell lines. The two cell lines were treated with 
actinomycin D (Act D, 10 μM) to block transcription, 
and the exponential decay was followed up to 10 h 
post-treatment. As shown (Figure 2A), the effect of 
Act D on RNA transcription, evaluated by agarose gel 
electrophoresis, clearly demonstrated a reduction of total 
RNA quantity, just after 6 h of treatment. The results 
indicate that the TRPV1 variants are expressed at different 
levels in both cell lines (Figure 2B). Higher TRPV1v3 
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Table 1: Comparative sequence analysis of the TRPV1 5’UTR variants
TRPV1v3 |ref|NM_080706.3| CTGCCGCTCACCCTATTCCAGGGACA-CAGTCTGCTTGGCTCTTCTGGAC 49
TRPV1v4 |ref|NM_080705.3| -----------------------GCA-GAGTGTGC--AG----TATAGAT 20
TRPV1v1 |ref|NM_080704.3| ----------------------GGCTCAGGCAGGCCTGG----CCCAGAG 24
TRPV1v0 |ref|NM_018727.5| -----------------------GCCCGGG--------A----CCC---- 11
gi|117306163|ref|NM_080706.3| TGAGCCATCCTCATCACCGAGATCCTCCCTGAATTCAGCCCACGACAGCC 99
gi|117306162|ref|NM_080705.3| TCAGCGTTTGTCG--ACTGA--------CTGAATG------ATAGCA-CA 53
gi|117306161|ref|NM_080704.3| TCA-CGCTGGCAACCAC-GAG------TTTGGGAA------GCAGTCGTA 60
gi|117306160|ref|NM_018727.5| -CA-CGGAGGCG------------------GGGAG------AC------- 28
gi|117306163|ref|NM_080706.3| ACCCCGGCCGTTTTCCTTGTTCTGTGTGGGGAGGGAGGCAGCGCGGTGGT 149
gi|117306162|ref|NM_080705.3| ATCCCGGCTGCTTCC--TGTT----------------------------- 72
gi|117306161|ref|NM_080704.3| TTCTCTCTCTCTCTCTCTCTC----------------------------- 81
gi|117306160|ref|NM_018727.5| ----CACTCT---------------------------------------- 34
gi|117306163|ref|NM_080706.3| TATCAACCTCACCCTGCAGAGGAGGCACCTGAGGCCCAGAGACGAGGAGG 199
gi|117306162|ref|NM_080705.3| -------------------------------------------------G 73
gi|117306161|ref|NM_080704.3| ----------------------------------------------TCTC 85
gi|117306160|ref|NM_018727.5| ----------------------------------------------TCTC 38
gi|117306163|ref|NM_080706.3| GATGGGTCTAACCCAGAACCACAGATGGC-TCTGAGCCGGGGGCCTGTCC 248
gi|117306162|ref|NM_080705.3| GCTGGGTTT-----------------GGT-T------------------- 86
gi|117306161|ref|NM_080704.3| TCTCAGTATCCATGA----------CAGTGTGAT---------------- 109
gi|117306160|ref|NM_018727.5| CCACACGAGCC--------------CAG---------------------- 52
gi|117306163|ref|NM_080706.3| ACCCTCCCAGGCCGACGTCAGTGGCCGCAGGA------CTGCCTGGGCCC 292
gi|117306162|ref|NM_080705.3| -----------------------------GGA------CTG---GGACCC 98
gi|117306161|ref|NM_080704.3| -----------------------------GGAGAGTCTCTGCC-GTGCC- 128
gi|117306160|ref|NM_018727.5| ------------------------------------CTCTCCC------- 59
gi|117306163|ref|NM_080706.3| TGCTAGGCCTGCTCACCTCTGAGGCCTCTGGGGTGAGAGGTTCAGTCCTG 342
gi|117306162|ref|NM_080705.3| --------------------------------GTCAGAGG---------- 106
gi|117306161|ref|NM_080704.3| --------------------------------ATCTGGGATGC------- 139
gi|117306160|ref|NM_018727.5| ---------------------------------TTCGAGTAGC------- 69
gi|117306163|ref|NM_080706.3| GAAACACTTCAGTTCTAGGGGGCTGGGGGC----AGCAGCAAGTTGGAGT 388
gi|117306162|ref|NM_080705.3| AAAA-----------------------GGC----AAC------------- 116
gi|117306161|ref|NM_080704.3| AAACCGTCCCTGTGTTCCCCACGTCCAGGCCGTAGAT------------- 176
gi|117306160|ref|NM_018727.5| AA----------------CCGCCTTCAAGC-------------------- 83
gi|117306163|ref|NM_080706.3| TTTGGGGTACCCTGCTTCACAGGGC----CCTTGGCAAGGAGGGCAGGTG 434
gi|117306162|ref|NM_080705.3| -----------------------GC----CGCTGACAAAGAACATTGCCG 139
(Continued )
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Figure 1: Secondary structure and free-energy value of the TRPV1 5’UTR variants and full-length sequences. Folding 
of 5’UTR TRPV1 variants and of the corresponding full length TRPV1 RNA transcripts predicted by the mFold program. Predicted 
secondary structures of lowest free energy were represented in kcal/mol.
gi|117306161|ref|NM_080704.3| -----------------------GCTCCCCGCCGGTCAGTCACTTAGTCG 203
gi|117306160|ref|NM_018727.5| ---------------------------------------TCAC------- 87
gi|117306163|ref|NM_080706.3| GGGTCTAAGGACAAGCAGTCCTTAC---TTTGGGAGT---CAACCCCGGC 478
gi|117306162|ref|NM_080705.3| A-----AAGG----------TTCA------TGGGAG------GCTCCGGC 162
gi|117306161|ref|NM_080704.3| T-----CAGATCG-------CCCGT---CCTGGTATCACAGTGCTTCTGT 238
gi|117306160|ref|NM_018727.5| --------AAGCA-------CCCGTGGGCCTGGGGT----GTGCCTGCGT 118
gi|117306163|ref|NM_080706.3| GTGGTGGCTGCTGCAG---GTTGCACACTGGGCCACAGAGGATCCAGCAA 525
gi|117306162|ref|NM_080705.3| ----------TAACAG---GTTGCACACTGGGCCACAGAGGATCCAGCAA 199
gi|117306161|ref|NM_080704.3| ------------TCAG---GTTGCACACTGGGCCACAGAGGATCCAGCAA 273
gi|117306160|ref|NM_018727.5| ------------CTAGCTGGTTGCACACTGGGCCACAGAGGATCCAGCAA 156
gi|117306163|ref|NM_080706.3| GGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTC 575
gi|117306162|ref|NM_080705.3| GGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTC 249
gi|117306161|ref|NM_080704.3| GGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTC 323
gi|117306160|ref|NM_018727.5| GGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTC 206
Gene bank accession number (gi and NM_) are indicated.
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level, followed by TRPV1v4, TRPV1v0 and TRPVv1 were 
observed. Time course analysis in Act D-treated samples 
evidences that the TRPV1v3 is the most stable with a Ct 
decay (Ct time 0 – Ct time 8, Δ Ctd) of 2, followed by 
TRPV1v4 (ΔCtd = 7.4), TRPV1v0 (ΔCtd = 8.3) and finally 
TRPV1v1 with a total decay, after 8 h of treatment. Overall, 
these results indicate that TRPV1 variants stability is 
correlated to their free energy value, confirming that 
TRPV1v3 is the most stable transcript.
TOP motif in 5’UTR regulates TRPV1 
translation
Since motifs present in 5’UTR are known to regulate 
protein translation, we analyzed TRPV1 5’UTR sequences 
by using RegRNA, a regulatory RNA motifs and element 
finder. As shown (Table 2), software analysis identified 
different regulatory elements in all of the TRPV1 5’UTR 
sequences. uORF motif was found in each TRPV1v1, v3, v4 
and an IRES was found in TRPV1v4 only. Regarding uORF, 
it is considered that all type of uORF can reduce protein 
expression, and specifically, three uORF properties are 
associated with greater inhibition: strong uAUG context, 
increased distance from the cap (cap-uORF distance > 50 
nt negative influence translation) and multiple uORF in the 
5’UTR. Sequence analysis of TRPV1 5’UTRs indicated 
similar properties in all TRPV1 5’UTR sequences: one 
single uORF is present in TRPV1v1,3,4, cap-uORF > 50 
and strong uAUG context. These analyses suggest that 
uORF in TRPV1 5’UTR should not influence different 
translation efficacy in TRPV1 5’UTR variants. TOP 
that makes mRNA translation sensitive to rapamycin 
(Rap) was found in all TRPV1 5’UTRs sequences. To 
address the importance of the 5’TOP motif in serving as 
inhibitory target of Rap in suppressing the translation of 
the TRPV1 5’UTR variants, we treated U87 and U251 
cell lines with 10 μM Rap for 24 h. TRPV1 protein 
levels, evaluated by western blot analysis, in Rap-treated 
cells, evidenced a strong reduction of TRPV1 translation 
compared with control cells (Figure 3A), suggesting 
Figure 2: Time-dependent TRPV1 5’UTR variant transcripts stability in U87 and U251 cell lines. A. Representative image 
of total RNA from Act D-treated U87 and U251 glioma cell lines analyzed by agarose gel electhrophoresis, up to 10 h post-treatment, B. Ct 
value at different times (2, 4, 6 and 8 h) post-Act D treatment. Time 10 h was omitted since no TRPV1 transcripts expression was detected. 
Data were obtained by RT-PCR analysis and represented one out of three separate experiments.
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Table 2: Motifs in TRPV1 5’UTR
TRPV1v0
No. RegRNA ID Location Length (nt) Sequence
1 TOP 53-63 11 CTCTCCCTTCG
2 GAIT 74-98107-134
25
28
CGGTTGCTACTGAAGGGAGAGCTG
GTGTGCCTGCGTCAGCTGGTTGCACAC
TRPV1v1
No. RegRNA ID Location Length (nt) Sequence
1 TOP
117~121
147~151
178~184
232~237
5
5
7
6
CTCTG
CCCTG
CTCCCCG
CTTCTG
2 uORF 97~174 78
ATGACAGTGTGATGGAGAGTCTCTGCCGTGC 
CATCTGGGATGCAAACCGTCCCTGTGT 
TCCCCACGTCCAGGCCGTAG
TRPV1v3
No. RegRNA ID Location Length (nt) Sequence
1 TOP
39~46
73~80
101-105
114-118
161-165
228-232
290-294
308-313
317-322
398-402
413-418
459-463
472-476
8
8
5
5
5
5
5
6
6
5
6
5
5
CTCTTCTG
CCTCCCTG
CCCCG
CCTTG
CCCTG
CTCTG
CCCTG
CCTCTG
CCTCTG
CCCTG
CCCTTG
CTTTG
CCCCG
2 uORF 201-314 114
ATGGGTCTAACCCAGAACCACAGATGGCTC 
TGAGCCGGGGGCCTGTCCACCCTCCCAGGC 
CGACGTCAGTGGCCGCAGGACTGCCTGGGC 
CCTGCTAGGCCTGCTCACCTCTGA
3 GAIT
27-51
110-134
110-136
110-137
392-416
438-465
109-133
25
25
27
28
25
28
25
CAGTCTGCTTGGCTCTTCTGGACTG
TTTTCCTTGTTCTGTGTGGGGAGGG
TTTTCCTTGTTCTGTGTGGGGAGGGAG
TTTTCCTTGTTCTGTGTGGGGAGGGAGG
GGGGTACCCTGCTTCACAGGGCCCT
TCTAAGGACAAGCAGTCCTTACTTTGGG
CGGCCGGGGTGGCTGTCGTGGGCTG
TRPV1v4
No. RegRNA ID Location Length (nt) Sequence
1 TOP 64-70156-160
7
5
CTTCCTG
CTCCG
2 uORF 43-165 123
ATGATAGCACAATCCCGGCTGCTTCCTGTT 
GGCTGGGTTTGGTTGGACTGGGACCCGTCA 
GAGGAAAAGGCAACGCCGCTGACAAAGAAC 
ATTGCCGAAAGGTTCATGGGAGGCTCCGGCTAA
4 GAIT 19-44 26 ATTCAGCGTTTGTCGACTGACTGAAT
RegRNA ID are represented, Location (as nucleotide position in 5’UTR mRNA region, Length in bases (b) and the relative 
nucleotide sequence. Terminal Oligopyrimidine Tract (TOP), Gamma Interferon activated inhibitor of Ceruloplasmin 
mRNA translation (GAIT), Upstream Open Reading Frame (uORF), Internal Ribosome Entry Site (IRES).
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that Rap, through 5’TOP motif, was able to suppress 
TRPV1 translation. In addition, by RegRNA analysis, 
the presence of an interferon-gamma (IFN-γ) activated 
inhibitor of translation (GAIT) element was determined 
in 5’ UTR of TRPV1v0, v3, v4. Since mRNAs with GAIT 
element are supposed to be negatively regulated by IFN-γ, 
we treated U87 and U251 cell lines with IFN-γ (100 
μM) for 24 h. After treatments, we analyzed the levels of 
TRPV1 transcript by western blot analysis, and the results 
evidenced a reduced expression of TRPV1 proteins in 
both glioma cell lines, mainly in U87 cells (Figure 3B), 
suggesting that IFN-γ was able to negatively regulate 
GAIT-TRPV1 variants translation, with levels of TRPV1 
protein likely sustained by the TRPVv1 expression that 
does not contain a GAIT element in its 5’UTR region.
TRPV1 5’UTR variants expression in glioma 
tissues and GSCs
To evaluate which TRPV1 5’UTR variant was 
expressed in glioma samples, we analyzed the expression 
of TRPV1 5’UTR variants in different glioma biopsies, 
from grade I to IV (n = 84) obtained from mixed patients 
(Supplementary Table 2), in normal brain (NB; n= 3) and 
in normal human astrocytes (NHA; n = 3) samples, by 
RT/PCR analysis. As shown NB, NHA and glioma grade I 
samples expressed at different levels all the 5'UTR TRPV1 
variant transcripts, while some samples resulted express 
the TRPV1 variants: grade II (10/12), III (12/20) and IV 
samples (38/40) (Table 3A). Furthermore, we found that 
the TRPV1 variants expression levels strongly decreased 
in TRPV1 positive (TRPV1+) glioma samples (grade 
III and IV) (Table 3A), except for the TRPV1v3, which 
expression was maintained in grade IV TRPV1+ samples 
(Table 3A). In fact, the TRPV1v3 was found to be the 
only TRPV1 5’UTR transcript expressed in the majority 
(n = 38/44) of GBM samples (Table 3A). Moreover, we 
found that the GBM samples showed different TRPV1v3 
relative expression (Rel. expr.) level, with 50% of GBM 
samples showing low expression (Rel. expr. ≤ 0.5), 36.4 
% with high expression (Rel expr. > 0.5) and 13.6 % with 
complete loss of TRPV1v3 expression (Rel. expr. 0) (Table 
3B). Evaluation of TRPV1 variant transcripts was also 
performed in Human Normal Progenitor Cells (HNPCs; 
n = 3), in Glioma Stem-like Cells (GSCs; n = 4) and in 
differentiated GSCs (dGSCs; n = 4). As shown (Table 
3C), HNPCs sample expressed all the TRPV1 variants, 
with similar levels found in NHA, two of four GSCs were 
shown to express TRPV1v3 only, while after differentiation 
all the GSCs showed expression of all the TRPV1 variants 
(Table 3C).
Taken together, these results revealed that TRPV1v3, 
which is the most stable TRPV1 5’UTR variants, is 
responsible for the TRPV1 expression in GBM and GSCs 
TRPV1+ samples, while the complete profile of TRPV1 
variants expression was present in NB, NHA and HNPC 
samples, and with different expression levels in Grade I-III 
gliomas.
TRPV1 expression and patient survival
TRPV1 mRNA expression was correlated with 
patients overall survival (OS). We first calculated the 
mean and median OS of GBM patients. We found that 
Figure 3: TRPV1 translation regulation by Rap and IFNγ in glioma cell lines. U87 and U251 glioma cell lines were treated 
with Rap (10 μM), or IFNγ (100 μM) and cellular lysates from treated glioma cells were immunoblotted with anti-TRPV1 antibody. 
GAPDH was used as loading control. Densitometric analysis was performed by using a ChemiDoc apparatus and software. Data presented 
are one out of three separate experiments.
Oncotarget81548www.impactjournals.com/oncotarget
the mean OS was 14.4 months and the median OS was 
11.0 months. Then, we evaluated the significance between 
patients survival (short OS survival < 12 months and 
long OS survival > 12 months) with the TRPV1v3 mRNA 
expression levels of all GBM patients (n = 44) by unpaired 
t-test. TRPV1v3 mRNA expression reached significance 
(p = 0.0009) for survival with short OS GBM patients, 
showing lower TRPV1v3 mRNA expression compared with 
long OS patients (Figure 4A). Moreover, on univariate 
analysis, survival curves were calculated according to the 
Kaplan–Meier method by evaluating TRPV1v3 mRNA 
expression of all patients. TRPV1v3 mRNA expression 
reached significance for survival (p = 0.0205) (Figure 
4B and Table 4A). Similar results were obtained in a 
subgroup of GBM patients (n = 6) showing complete 
loss of TRPV1v3 mRNA expression, as respect to TRPV1 
expressing GBM patients (n = 38) (p = 0.0006) (Figure 4B 
and Table 4B). Thus, low or absent of TRPV1v3 expression 
strongly correlates with short survival in GBM patients. 
Additionally we performed a multivariate analysis based 
on the Cox regression model to test the influence of 
TRPV1v3 mRNA expression on the survival of all patients 
or those with deleted TRPV1v3 expression. We found that 
the degree of TRPV1v3 mRNA expression retained its 
significance as an independent prognostic factor in all 
group of patients (P = 0.0008) and in the subgroup with 
deleted TRPV1v3 expression (P = 0.0011) (Figure 4C and 
Table 4B).
DISCUSSION
Deregulation of gene expression is a hallmark 
of cancer cells. Acquiring or maintaining a specific 
profile of expressed proteins may enable the tumor 
cells to grow, migrate or survive to apoptotic stimuli. 
Modifications of mRNA stability and/or translation 
efficiency are increasingly reported in cancers [15, 
26]. The UTRs flanking the coding region in mature 
Table 3: TRPV1v3 expression in GBM samples and GSCs
A)
TRPV1 5’UTR 
variants
NB
(n=3/3)
NHA
(n=2/2)
Grade I
(n=8/8)
Grade II
(n=10/12)
Grade III
(n=12/20)
Grade IV
(n=38/44)
TRPV1v0 0.42 ± 0.4 0.22 ± 0.01 0.62 ± 0.22 0.34 ± 0.01 0.16 ± 0.01 0
TRPV1v1 0.61 ± 0.09 0.72 ± 0.11 0.33 ± 0.12 0.26 ± 0.01 0.03 ± 0.01 0
TRPV1v3 0.85 ± 0.12 0.77 ± 0.13 1.12 ± 0.20 0.81 ± 0.19 0.44 ± 0.1 0.43 ± 0.2
TRPV1v4 0.64 ± 0.11 0.61 ± 0.08 0.16 ± 0.01 0.40 ± 0.02 0.22 ± 0.1 0
B)
TRPV1v3 (n= 6/44) (n= 22/44) (n=16/44)
Rel. Expr. 0 ≤ 0.50 > 0.50
% of samples 13.6 50 36.4
C)
TRPV1 5’UTR variants HNPC
(n=3/3)
GSC
(n=2/4)
dGSC
(n=4/4)
TRPV1v0 0.42 ± 0.02 0 0.23 ± 0.01
TRPV1v1 0.33 ± 0.02 0 0.27 ± 0.01
TRPV1v3 1.02 ± 0.13 0.25 ± 0.01 0.38 ± 0.02
TRPV1v4 0.22 ± 0.01 0 0.15 ± 0.01
A) TRPV1 5’UTR variants relative expression (Rel. Exp) levels in Normal Brain (NB), Normal Human Astrocytes (NHA) 
and in glioma biopsies from grade I to IV. B) TRPV1v3 expression levels in GBM samples, subdivided in three categories: 
no TRPV1v3 expression (Rel. Expr. = 0), low TRPV1v3 (Rel. Expr. ≤ 0.50) and high TRPV1v3 (Rel. Expr. > 0.50). TRPV1v3 
relative expression levels are indicated. C) TRPV1 5’UTR variants relative expression (Rel. Exp) levels in human normal 
progenitor cells (HNPC), glioma stem-like cells (GSC) and dGSC (differentiated glioma stem-like cells). n: indicates 
the number of samples analyzed. A, B) n: indicates the number of TRPV1 positive samples respect to the total samples 
analyzed. A-C) Data are represented as mean of TRPV1 relative expression ± S.D. of three-separated RT/PCR analysis. 
Relative values were normalized to GAPDH expression level.
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mRNA regulate translation or mRNA stability through 
diverse mechanisms, representing an extra level of gene 
expression control [26-28]. An increasing number of 
reports highlight the effect of simple sequence elements 
or secondary and tertiary structures of the 5’ UTR in 
affecting the translation efficiencies of proto-oncogenes 
or tumor suppressing genes [15], neurotransmitter 
receptors [29] and ion channels [30]. Elements in the 5’ 
UTR can mediate translational regulation via the 5’-cap 
or the secondary structure, and stable 5’ UTR structures 
can interfere with translation by reducing the accessibility 
for the translational machinery and ribosomal scanning 
[31-33]. The TRPV1 channel, whose regulation was 
investigated in glioma, evidenced different expression 
Figure 4: TRPV1v3 mRNA expression correlates with survival. A. Distribution of TRPV1v3 mRNA expression in short survival 
(OS < 12 months) and long survival (OS > 12 months) GBM patients (n = 44 GBM specimens). Statistical analysis was performed by 
Unpaired t test at two-tailed (P < 0.05) value. B. Kaplan-Meier survival analysis for TRPV1v3 expressing glioma patients, illustrating 
an association between: A) survival and TRPV1v3 mRNA expression based on two categories, high (fold > 2.0) and low (fold < 2.0) 
TRPV1v3 levels. C. survival and TRPV1v3 mRNA expression based on two categories, TRPV1v3 mRNA loss vs expression (n = 44 samples). 
Associated log-rank test and Cox regression P-values were indicated.
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patterns. Our results indicated that among the TRPV1 
5’UTR variants, TRPV1v3 has the most structured and 
stable 5’UTR sequence, since its secondary 5’UTR 
structure shows the lowest free energy compared with 
the other 5’UTR variants. Moreover, experiments using 
Act D confirmed that TRPV1v3 in GBM is the most stable 
TRPV1 5’UTR transcript. Secondary structure and 5’UTR 
elements can function as major regulatory tool in 5’UTR 
and are prevalent among mRNAs poorly translated under 
normal conditions [34]. Our data suggest that TRPV1v3 
is the only representative transcript expressed in TRPV1 
positive GBM samples analyzed. Further computational 
prediction analysis revealed that all TRPV1 5’UTR 
variants contain a common translational sequence, named 
TOP, and TOP mRNAs remain sensitive to Rap treatment. 
In various cell lines, the degree of TOP inhibition by Rap 
varies, indicating that the effects of Rap are most likely 
cell type dependent [35-37]. Our results indicated that 
in GBM cell lines, treated with Rap, the TRPV1 protein 
levels decrease, suggesting that TRPV1 translation is 
sensitive to Rap. Since the pro-survival role of autophagy 
in tumors, including GBM [38], down-regulation of 
TRPV1 protein by a canonical autophagic inducer is 
interesting also in the view of a counterattack role of the 
TRPV1 channel in autophagy, through the induction of 
apoptosis in GBM cells [22]. Another regulatory element 
that was evidenced by computational analysis, is the GAIT 
element, that was found in 5’ UTR of TRPV1v0,v3,v4. GAIT 
element has been experimentally demonstrated to be 
sufficient for mRNA translational silencing, by IFN-γ, in 
human U937 monocytic cells [39]. Our results confirmed 
that INF-γ is able to reduce TRPV1 protein levels 
compared with untreated cells, suggesting that GAIT 
can be another 5’UTR element able to regulate TRPV1 
translation. Altogether, these results evidenced the role 
of 5’UTR in TRPV1 translation and stability, suggesting 
novel potential mechanisms to regulate TRPV1 functions 
in human GBM cell lines. Our and other research data 
indicate that triggering of TRPV1 by synthetic or 
endogenous ligands activates apoptotic cell death pathway 
[22, 23]. Thus, it is conceivable that the reduced or lost 
expression of TRPV1v3, the only TRPV1 variant expressed 
in GBM, could represent a mechanism by which the 
GBM cells evade pro-apoptotic signals. Moreover, this 
hypothesis was supported by the analysis in grade I-III 
gliomas, where we found that TRPV1 variant expression 
levels were inversely correlated to the glioma grade. In 
addition our findings evidenced that, as in TRPV1+-GBM 
samples, GSCs maintain only TRPV1v3 transcript. Since 
different mechanisms mediate the resistance of GSCs 
to cytotoxic therapies and to pro-apoptotic signals [40-
42], including down-regulation of TRPV1 [23], this data 
suggest that reduced TRPV1 expression in GSCs could be 
associated to their acquired resistance, as in GBM.
Furthermore, herein we showed that by inducing 
GSCs differentiation the TRPV1v3 expression increased, 
and the expression profile of dGSCs was similar to that 
found in low-grade glioma samples. Accordingly to our 
data, loss of TRPV1 was associated to proliferation of 
neural stem cell and neurogenesis reduction [23].
In support of this hypothesis, we found that the 
reduction of TRPV1v3 is accompanied by poor prognosis, 
which is also worsened by the complete loss of TRPV1v3 
mRNA expression. In the same view, TRPV1 mRNA was 
found to be over-expressed in GBM tissues as respect to 
NB and TRPV1 expression was significantly higher (5-fold) 
Table 4: Statistical analysis of TRPV1v3 in GBM
Table 4A: Univariate Kaplan-Meier survival analysis and TRPV1v3 mRNA expression (log-rank test)
All patients (n = 44)
N° events (n = 38)
All patients (n = 44)
N° events (n = 44)
Log-rank test P-value Log-rank test P-value
TRPV1v3 (low/high) 5.367 0.0205
TRPV1v3 (loss/expression) 11.90 0.0006
Table 4B: Multivariate Cox proportional hazard regression analysis of Kaplan-Meier survival analysis of TRPV1v3 
mRNA expression in relation to survival rates
Relative risk (95% CI)
All patients (n = 38/44)
TRPV1v3 (low/high) 2.25 (1,13-4.45) P = 0,0008
Relative risk (95% CI)
All patients (n = 6/44)
TRPV1v3( loss/expression) 17.1 (3.40-85.10) P = 0.0011
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in GBM patients with higher OS (more than 12 months) 
as respect to that showing lower OS (less than 12 months) 
[25]. No data on the expression of TRPV1 variants in 
tumors have been provided so far. The only data in cancer 
is referred to TRPV1 wild type. Thus, in hepatocellular 
carcinoma, TRPV1 expression correlates with better 
prognosis of patients [43], while in bladder cancer its 
reduction represents a prognostic negative biomarker [21].
Overall our results suggest that TRPV1v3 expression 
is a potential negative prognostic marker for patients with 
GBM. In fact, the reduction or null expression of TRPV1v3 
transcript was associated with a short survival of all 
these patient groups. In a multivariate Cox proportional 
hazards regression model, TRPV1v3 expression reached 
significance as an independent prognostic factor for 
survival considering all patients and the subgroup 
characterized by loss of TRPV1v3 expression.
All together, these data suggested that TRPV1 
could have a role in tumor aggressiveness, since loss of 
reduction of TRPV1 expression is associated with a more 
proliferative tumor, as also reported for others cancer cell 
types [20, 22, 43].
In conclusion our results, showing that the TRPV1v3 
has the lowest free energy in its secondary 5’UTR 
structure and the highest 5’UTR sequence stability, 
suggest that it may represent a potential prognostic marker 
for patients with GBM. As an independent prognostic 
factor for poor disease outcome, TRPV1v3 may be useful 
to improve appropriate selection of post-operative follow-
up protocol for individual patients. Further studies with a 
more representative number of GBM samples, are required 
to completely assess the role of TRPV1 5’UTR identified 
in GBM patients.
MATERIALS AND METHODS
Software for mRNA structure analysis
RegRNA 2.0 was used for identifying functional 
RNA motifs in 5’ UTR TRPV1 RNA sequence [44]. 
MView reformats the results of a sequence database search 
(BLAST, FASTA, etc) or a multiple alignment (MSF, 
PIR, CLUSTAL, etc) and was used for TRPV1 variant 
transcripts comparative analysis [45]. The structure and 
the free energy (ΔGs) of the TRPV1 variant transcripts 
were calculated using RNAfold [46].
Cell cultures and human bioptic samples
U87 and U251 human glioma cell lines were 
obtained from the American Type Culture Collection 
(LGC Promochem, Teddington, UK). Glioma cell lines 
were growth in Dulbecco’s Modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 2 mmol/L-
glutamine, 100 IU/mL penicillin, 100 μg streptomycin at 
37°C, 5% CO2 and 95% of humidity.
Formalin-fixed paraffin-embedded glioma tissues 
from human tumor biopsies surgically removed from 
patients who gave informed consent to the study (n = 
84), were kindly provided by Prof. Felice Giangaspero 
(I.N.M., Neuromed, Pozzilli, Isernia, Italy) as previously 
described [47]. GSC lines previously characterized [42] 
were cultured in a serum free medium supplemented 
with 20 ng/ml of epidermal growth factor (EGF) and 
10 ng/ml of basic fibroblast growth factor (bFGF). For 
differentiation, GSC lines were grown for 15 days, in 
medium supplemented with 5% fetal bovine serum (FBS). 
HNPC were purchased from Cambrex, (UK) and cultured 
folllowing manufacturing instruction.
Compounds
Rap, Act D and IFN-γ were purchased from Sigma-
Aldrich (Bristol, UK), and aliquots of 25 mM were 
prepared according to manufacturing instruction.
RT/PCR analysis
Total RNA (RNAt), from cell lines, was extracted 
using the RNeasy Mini kit (Qiagen, Milan, IT). RNAt 
from GBM biopsies was extracted with RNeasy FFPE kit 
(Qiagen, Milan, IT), as previously described [44]. Total 
RNA from NHA and NB were purchased (Clonetech, 
USA). Complementary DNA (cDNA) was synthetized 
from 1 μg of RNAt using the high-capacity cDNA archive 
kit (Life Technology, Milan, IT), in a total volume of 
25 μl. Real Time Quantitative PCR (qRT-PCR), for 
TRPV1 variants was performed using specific primers 
(Supplementary Table 3) and human GAPDH RT2 qPCR 
Primer assay (Qiagen) were used to normalize qRT-
PCR data. The following thermal cycling conditions: 3’ 
at 95°C; 35 cycles of 10” at 95°C, 20” at 60°C, 20” at 
72°C; and finally 50” at 72°C, using iQ5 Thermal Cycler 
(Bio-Rad, Hercules, CA). Melting curve was performed to 
verify primers specificity. One μl of cDNA was used in a 
final volume of 25 μl, with 2X RT2 SYBR® Green qPCR 
Master mixes (Qiagen) and each sample was amplified in 
triplicate. Measurement of GAPDH transcript level was 
used to normalize TRPV1 variants levels. TRPV1 variants 
levels were calculated by the 2−ΔΔCt method and expressed 
as relative fold compared with the corresponding control.
RNA stability assay
Glioma cell lines were treated up to 12 h with Act 
D (10 μ g/ml) and RNAt was isolated from the cell pellet 
using RNeasy mini kit, and eluted in 50 μl of H2O. The 
same volume of RNAt samples were run in 1.5% agarose 
gel electrophoresis, then gel was visualized by UV trans-
illuminator and the image of the gel was acquired by 
Chemi-Doc (BioRad). Real time-PCR with the specific 
TRPV1 5’UTR variants primers was performed. For each 
sample, the amount of TRPV1 transcripts was evaluated 
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relative to 1 μg of RNAt, by Real-Time PCR. Briefly, first-
strand cDNA was synthetized using 1 μg of RNAt and 10 
ng of cDNA, for each sample, was amplified with specific 
TRPV1 variant primers. Experiments were performed in 
triplicate.
Western blot analysis
Glioma cell lines were lysed as described previously 
[44]. Twenty micrograms of the lysates were separated on 
a SDS polyacrylamide gel, transferred onto Hybond-C 
extra membranes (GE Healthcare), blocked with 5% low-
fat dry milk in PBS-Tween 20, immunoblotted with mouse 
monoclonal anti-TRPV1 antibody (Ab) (1:1000, Sigma 
Aldrich), and mouse monoclonal anti-glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) Abs overnight and 
then incubated with HRP-conjugated Ab (1:2000, Cell 
Signaling) for 1 h. Immunostaining was revealed using an 
enhanced chemiluminescence Western blotting analysis 
system (GE Healthcare). Densitometric analyses were 
performed by ChemiDoc using the Quantity One software 
(Bio-Rad).
TOP analysis
Glioma cell lines were treated for 24 h with Rap (10 
μM), then cell pellets was lysed for western blot analysis.
GAIT analysis
GAIT regulation of TRPV1 variants translation was 
determined, by treating glioma cell lines with IFN-γ (100 
μM) for 24 h. Western blot analysis were performed to 
evaluate TRPV1 protein levels.
Statistical analysis
The statistical significance of Ct variation levels was 
determined by Student’s t-test. Statistical analysis was 
performed using the Kruskal–Wallis test for comparison 
of TRPV1 mRNA expression groups. P-value ≤0.05 was 
considered significant. Patient follow-up was evaluated 
as the number of months from the date of the diagnostic 
surgical procedure to that of last visit or death. Survival 
time was defined as the period between the time of 
diagnosis and the time of death.
Statistical analysis was performed using GraphPad 
Prism 9.0 software (GraphPad software, San Diego, 
CA, USA). Univariate survival analysis was performed 
according to the Kaplan–Meier method, and differences 
in the survival curves were assessed with the log-rank test. 
Multivariate survival analysis was performed using Cox’s 
proportional regression analysis and the relative risk was 
calculated with 95% confidence interval (CI). A P-value 
≤0.05 was considered statistically significant.
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